Companies /Healthcare

DaVita Inc

NYSE: DVA Medical Care Facilities
$174.56
▲ $0.49 (+0.28%) today
Markets closed · 12:13pm ET

24/7 Wall St. View

DVA at a Glance

Valuation
Market cap
$11.0B
P/E ratio
13.2
Profitability
Revenue (TTM)
$14.2B
Profit margin
6.5%
EPS (TTM)
$13.21
Price
52-week range
$101 – $247
24/7 target
$217.40
Street target
$222.29
Earnings
Next report
Feb 1, 2027

Headquartered in Denver, CO Fiscal year ends December NYSE: DVA davita.com

About DaVita

DaVita Inc. (NYSE: DVA) is a provider of kidney care services, primarily outpatient dialysis for patients with end-stage kidney disease.

**Scale (as of September 30, 2026)**
- About 298,100 patients served
- 3,269 outpatient dialysis centers in total
- 2,671 centers in the United States
- 598 centers in 14 other countries

**Business lines**
- **U.S. dialysis:** The core business, generating the large majority of revenue. It is paid by Medicare, Medicare Advantage, Medicaid and higher-paying commercial insurers.
- **Integrated kidney care (IKC):** Risk-based and value-based care arrangements, including special needs plans and Comprehensive Kidney Care Contracting model participation. It covers roughly 80,800 risk-based patients and about $6.4 billion of annualized medical spend.
- **Other U.S. ancillary services.**
- **International dialysis operations,** including a business in China that incurred an impairment this quarter.

**Other investments**
DaVita holds equity investments, including in Mozarc Medical Holding LLC.

**Capital structure**
The company operates with significant leverage (about $10.8 billion of debt) and returns capital mainly through share repurchases. Updated

Latest Activity

DVADaVita
Q3 2026
EPS
$3.82
est $3.57+6.9%
Revenue
$3.58B
est $3.52B+1.7%

DaVita topped both EPS and revenue estimates and lifted the floor of its 2026 adjusted EPS guidance to $14.30, yet the stock fell anyway. The culprit: a $62 million non-cash China impairment and rising patient care costs per treatment.

Quarterly EPS — reported vs estimate

DVA Coverage

Frequently Asked Questions

What does DaVita do?

DaVita Inc. (NYSE: DVA) is a provider of kidney care services, primarily outpatient dialysis for patients with end-stage kidney disease. **Scale (as of September 30, 2026)** - About 298,100 patients served - 3,269 outpatient dialysis centers in total - 2,671 centers in the United States - 598 centers in 14 other…

What is the DVA stock price target?

24/7 Wall St.'s 12-month price target for DVA is $217.40, rated Buy. The Wall Street consensus target is $222.29. DVA price prediction →